Literature DB >> 2447436

Regulation of lipoprotein metabolism by adrenergic mechanisms.

V J Dzau1, F M Sacks.   

Abstract

The available data on the adrenergic influences on lipoprotein metabolism are reviewed. It is clear that the influences are complex. It appears that adrenergic stimuli act at multiple sites in the lipoprotein metabolic pathways. This explains in part, the confusion in interpreting the literature. Based on the effects of alpha- and beta-adrenergic blocker administration in animals and humans, it is clear that the net effect of alpha 1-receptor stimulation is a decrease in HDL cholesterol and an increase in LDL cholesterol and VLDL triglyceride. On the other hand, beta-receptor stimulation will result in a net reduction of LDL and an increase in HDL. Further studies to elucidate the exact mechanism of action by the adrenergic stimuli on lipoprotein metabolism should provide insights into the relationship between the adrenergic nervous system and atherosclerosis and an enhanced understanding of the mechanisms by which antihypertensive-adrenergic mechanisms--alpha 1-Inhibition--Atherosclerosis--Serum lipids.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447436

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Dietary sodium restriction: adverse effect on plasma lipids.

Authors:  A M Sharma; H R Arntz; A Kribben; S Schattenfroh; A Distler
Journal:  Klin Wochenschr       Date:  1990-07-05

Review 2.  Do partial agonist beta-blockers have improved clinical utility?

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

3.  Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.

Authors:  T L Foxall; G T Shwaery; A F Stucchi; R J Nicolosi; S S Wong
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

4.  Sympathoadrenergic overactivity and lipid metabolism.

Authors:  A Grynberg; D Ziegler; H Rupp
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

5.  The relationship between plasma endothelin-1, nitric oxide levels, and heart rate variability in patients with coronary slow flow.

Authors:  Hasan Pekdemir; Dilek Cicek; Ahmet Camsari; M Necdet Akkus; V Gokhan Cin; Oben Doven; H Tuncay Parmaksiz; M Tuna Katircibasi; I Turkay Ozcan
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

6.  The associations of high-density lipoprotein subclasses with insulin and glucose levels, physical activity, resting heart rate, and regional adiposity in men with coronary artery disease: the Stanford Coronary Risk Intervention Project baseline survey.

Authors:  P T Williams; W L Haskell; K M Vranizan; R M Krauss
Journal:  Metabolism       Date:  1995-01       Impact factor: 8.694

7.  Interrelationships among measures of autonomic activity and cardiovascular risk factors during orthostasis and the oral glucose tolerance test.

Authors:  E Peles; D S Goldstein; S Akselrod; H Nitzan; M Azaria; S Almog; D Dolphin; H Halkin; M Modan
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

8.  Epidemiology of cardiovascular disease risk factors in Catalonia (Spain).

Authors:  P Plans; H Pardell; L Salleras
Journal:  Eur J Epidemiol       Date:  1993-07       Impact factor: 8.082

9.  Effect of percutaneous transluminal coronary angioplasty on QT dispersion and heart rate variability parameters.

Authors:  Ali Aydinlar; Tunay Sentürk; Bülent Ozdemïr; Aysel Aydin Kaderlï; Ozlem Aydin
Journal:  Cardiovasc J Afr       Date:  2009 Jul-Aug       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.